From Process Safety Challenges to Cost-Efficient Phase III Manufacturing Success

How Neuland developed an innovative, lower-cost process and successfully scaled the manufacture of a high-purity pharmaceutical intermediate for Phase III clinical trials.

In this case study, discover how Neuland partnered with a US-based pharmaceutical innovator to replace a non-scalable, flammable laboratory process with a safer and more cost-effective manufacturing route. Through process optimization, impurity control, and successful scale-up, Neuland delivered high-purity intermediate batches that met stringent quality specifications while supporting Phase III clinical manufacturing timelines.

Key Takeaways

• Developed a safer and lower-cost manufacturing process using an alternative reagent.
• Reduced individual impurities to below 0.1%.
• Achieved more than 99% purity in the final intermediate.
• Reduced residual iron levels to below 10 ppm.
• Successfully completed six 250 kg GMP manufacturing batches.
• Delivered the material one week ahead of schedule.
• Introduced humidity-controlled packaging for a highly moisture-sensitive intermediate.
• Developed a commercially scalable process with consistent yields of 70–75%.

This case study demonstrates how innovative process chemistry, effective impurity management, and scalable manufacturing expertise can transform a laboratory-scale process into a reliable, cost-efficient supply chain for late-stage clinical development.